cAMPfield is a biopharmaceutical company developing prifemilast, a potentially best-in-class oral PDE4 inhibitor for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company in-licensed prifemilast from Newsoara Biopharma and was founded by Mountainfield Venture Partners alongside industry executives who played key roles in the development and commercialization of major biologics.